RunaPharma
ActiveSummary
RunaPharma has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€18,060) and a net result of -€1,293. Equity is shrinking by about 8.3% per year across the filed financial years. Its solvency ranks better than 5% of 2,778 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Articles of association
What the company does
- Name clauseThe name the company operates under according to its articles.
- RunaPharma
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse Gewest” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- Each director alone
- Board ruleHow the board is made up, meets and takes decisions.
- “Bestuurders, met of zonder beperking van duur” (deed in Dutch)“Aantal, duur van opdracht en, indien meerdere bestuurders, bevoegdheid, algemene vergadering die benoemt” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- First Saturday of December at 10:00
Oversight and winding up
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Na aanzuivering van alle schulden, lasten en kosten of consignatie, na herstelling evenwicht tussen niet-volgestorte en meer-volgestorte…” (deed in Dutch)